Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternate-day Atripla versus standard daily Atripla in virologically suppressed adults with HIV-1
2011-004038-33Phase 3Completed
- Sponsor
- National Institute for Infectious Diseases Lazzaro Spallanzani
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tenofovir disoproxil fumarate in Human immunodeficiency virus infection type 1 and human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute for Infectious Diseases Lazzaro Spallanzani. Primary endpoints: Primary efficacy endpoint and Virologic suppression endpoint. Started Dec 2011; status: completed.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2011-004038-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004038-33.